GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (MEX:AGIO) » Definitions » Cyclically Adjusted Book per Share

Agios Pharmaceuticals (MEX:AGIO) Cyclically Adjusted Book per Share : MXN209.99 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Agios Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Agios Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2024 was MXN217.551. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN209.99 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Agios Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 12.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-25), Agios Pharmaceuticals's current stock price is MXN397.93. Agios Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was MXN209.99. Agios Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 1.89.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Agios Pharmaceuticals was 3.09. The lowest was 1.35. And the median was 1.90.


Agios Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Cyclically Adjusted Book per Share Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 240.11 274.75 267.31

Agios Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 258.46 219.85 258.20 267.31 209.99

Competitive Comparison of Agios Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Agios Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agios Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=217.551/131.7762*131.7762
=217.551

Current CPI (Mar. 2024) = 131.7762.

Agios Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 75.557 100.560 99.012
201409 80.521 100.428 105.656
201412 168.715 99.070 224.414
201503 174.497 99.621 230.820
201506 169.550 100.684 221.909
201509 168.802 100.392 221.573
201512 157.423 99.792 207.878
201603 150.965 100.470 198.005
201606 140.577 101.688 182.172
201609 184.753 101.861 239.012
201612 175.107 101.863 226.530
201703 136.556 102.862 174.941
201706 190.305 103.349 242.650
201709 167.902 104.136 212.468
201712 151.040 104.011 191.359
201803 273.294 105.290 342.044
201806 279.192 106.317 346.049
201809 244.461 106.507 302.461
201812 231.881 105.998 288.274
201903 205.111 107.251 252.015
201906 174.166 108.070 212.372
201909 150.314 108.329 182.848
201912 176.611 108.420 214.657
202003 213.142 108.902 257.912
202006 186.661 108.767 226.148
202009 153.381 109.815 184.055
202012 114.683 109.897 137.515
202103 672.453 111.754 792.929
202106 572.092 114.631 657.657
202109 524.152 115.734 596.805
202112 487.788 117.630 546.452
202203 438.903 121.301 476.805
202206 412.549 125.017 434.855
202209 384.817 125.227 404.944
202212 389.927 125.222 410.337
202303 336.387 127.348 348.085
202306 296.597 128.729 303.619
202309 276.427 129.860 280.507
202312 246.070 129.419 250.551
202403 217.551 131.776 217.551

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Agios Pharmaceuticals  (MEX:AGIO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Agios Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=397.93/209.99
=1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Agios Pharmaceuticals was 3.09. The lowest was 1.35. And the median was 1.90.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Agios Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals (MEX:AGIO) Business Description

Industry
Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Agios Pharmaceuticals (MEX:AGIO) Headlines

From GuruFocus

Agios Appoints Jeffrey Capello to Board of Directors

By sperokesalga sperokesalga 04-19-2023